20 Dec 2021 argenx announces U.S. Food and Drug Administration (FDA) approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis Member news
16 Nov 2021 New study demonstrates Idylla™ EGFR Mutation Test (CE-IVD) shortens time to patient management decisions for patients with non-small cell lung cancer Member news
15 Nov 2021 Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis Member news
21 Oct 2021 reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase Member news
12 Oct 2021 Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging Member news
12 Oct 2021 Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
